<DOC>
	<DOCNO>NCT00516152</DOCNO>
	<brief_summary>The primary objective study assess safety efficacy perform unrelated stem cell transplant use intravenous busulfan fludarabine preparative therapy tacrolimus plus methotrexate GVHD prophylaxis regimen . The goal demonstrate safety , aim transplant relate mortality rate ( TRM ) &lt; equal 40 % 100 day . A TRM &gt; equal 60 % consider unacceptable . Another goal demonstrate efficacy show overall survival &gt; 40 % 1-year following transplant .</brief_summary>
	<brief_title>Phase II Study Evaluating Busulfan Fludarabine Preparative Therapy Adults With Hematopoietic Disorders Undergoing MUD SCT</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>No fully singleantigen mismatched sibling donor available donate stem cell . Age &gt; 15 &lt; 61 ECOG PS &lt; equal 2 Adequate renal function serum creatinine &lt; 2.0 mg/dl Pulmonary diffusing capacity &gt; 40 % predict Cardiac ejection fraction &gt; 40 % measure radionuclide wall motion study echocardiography No active liver disease . Total bilirubin must &lt; equal 2.0 mg/dl . Alkaline phosphatase AST must less three time upper limit normal . Patients hepatitis C active hepatitis B eligible liver biopsy perform &lt; equal grade 2 inflammation . Patients wtih history HBV infection test HBeAg , antiHBe HBV DNA ( quantitative ) . Patients active HBV viral replication receive antiviral therapy . Negative serology human immunodeficiency virus ( HIV ) Available HLAmatched donor ( see HLA compatibility requirement ) Signed informed consent recipient Ongoing active infection Pregnancy and/or nurse Active , uncontrolled CNS leukemia Opinion BMT Committee autologous miniallogeneic transplant would preferable form treatment Receipt chemotherapy within 3 week study entry except hydroxyurea imatinib mesylate . Use interferon within 3 month start therapy .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Matched Unrelated Donor</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Busulfan</keyword>
	<keyword>fludarabine</keyword>
	<keyword>Hematopoietic Disorder</keyword>
</DOC>